Recaticimab

Q: What did studies of Recaticimab find?

Studies of Recaticimab measured 1 outcome; the most studied are LDL cholesterol (2 studies).

Recaticimab has been studied in 2 papers since 2026: 1 trial in people, 1 review; 2 in the past year. The newest story, Oct 29, 2026: “Recaticimab lowered cholesterol with or without coronary disease”.

Intervention

2 papers study it2 findingsUpdated Oct 29, 2026

2 new papers in 30 daysSee all 2

“recaticimab significantly reduced LDL-C and other atherogenic lipids (non-HDL-C and ApoB) compared with placebo in both patients with and without CAD across both dosing regimens”

Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysisESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.4135

None of its findings points the other way.

2 independent labs in 1 country

Human trial1

Studies in people

1 study gave recaticimab to people and measured what changed.

down: Decreases LDL cholesterolall P<0.001
Review of trials1,120 people pooledBoth47 to 57 years12 or 16 weeks
Midlife adults; in patients with and without coronary artery disease
ESC Congress 2026 abstract, Oct 26, 2026

What did studies of Recaticimab find?

Studies of Recaticimab measured 1 outcome; the most studied are LDL cholesterol (2 studies).

LDL cholesterol

downin humans2

2 studies

Recaticimab decreases LDL cholesterol in patients with and without coronary artery disease (all P<0.001).
“recaticimab significantly reduced LDL-C and other atherogenic lipids (non-HDL-C and ApoB) compared with placebo in both patients with and without CAD across both dosing regimens”
Human trialin patients with and without coronary artery disease150 mg Q4W or 300 mg Q8W
Recaticimab lowered cholesterol with or without coronary disease
ESC Congress 2026 abstractOct 26, 2026
Recaticimab decreases LDL cholesterol in humans (dyslipidemia; compared with placebo) (-47.31 percentage points relative to placebo; 95% CI -49.87 to -44.75).
“At week 12, recaticimab reduced LDL-C by 47.31 percentage points relative to placebo”
Reviewdyslipidemia; compared with placebohumanized anti-PCSK9 monoclonal antibody12 weeksn = 1,657
Efficacy and Safety of Recaticimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment
Cardiology in reviewOct 29, 2026

Latest

2 papers in 12 months

Cardiology in ReviewOct 29

Efficacy and Safety of Recaticimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment

Meta-analysis of randomized trialsDyslipidemia

Paper

ESC Congress 2026 AbstractOct 26

Recaticimab lowered cholesterol with or without coronary disease

A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.

Meta-analysis · 1,120 peopleInterventions